- Home
- TNGX vs TSHA Comparison
TNGX vs TSHA Comparison
Compare TNGX & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- TSHA
- Stock Information
- Founded
- TNGX 2014
- TSHA 2019
- Country
- TNGX United States
- TSHA United States
- Employees
- TNGX N/A
- TSHA N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- TNGX Health Care
- TSHA Health Care
- Exchange
- TNGX Nasdaq
- TSHA Nasdaq
- Market Cap
- TNGX 351.2M
- TSHA 728.4M
- IPO Year
- TNGX N/A
- TSHA 2020
- Fundamental
- Price
- TNGX $6.01
- TSHA $2.68
- Analyst Decision
- TNGX Strong Buy
- TSHA Strong Buy
- Analyst Count
- TNGX 6
- TSHA 6
- Target Price
- TNGX $12.20
- TSHA $8.17
- AVG Volume (30 Days)
- TNGX 2.7M
- TSHA 2.8M
- Earning Date
- TNGX 08-06-2025
- TSHA 08-11-2025
- Dividend Yield
- TNGX N/A
- TSHA N/A
- EPS Growth
- TNGX N/A
- TSHA N/A
- EPS
- TNGX N/A
- TSHA N/A
- Revenue
- TNGX $40,990,000.00
- TSHA $7,224,000.00
- Revenue This Year
- TNGX N/A
- TSHA N/A
- Revenue Next Year
- TNGX N/A
- TSHA N/A
- P/E Ratio
- TNGX N/A
- TSHA N/A
- Revenue Growth
- TNGX 10.09
- TSHA N/A
- 52 Week Low
- TNGX $1.03
- TSHA $1.05
- 52 Week High
- TNGX $12.02
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- TNGX 76.36
- TSHA 59.68
- Support Level
- TNGX $5.34
- TSHA $2.33
- Resistance Level
- TNGX $6.40
- TSHA $2.51
- Average True Range (ATR)
- TNGX 0.50
- TSHA 0.14
- MACD
- TNGX -0.02
- TSHA 0.02
- Stochastic Oscillator
- TNGX 84.08
- TSHA 90.43
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.